{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T22:38:26Z","timestamp":1722897506196},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.leukres.2014.04.002","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T05:45:58Z","timestamp":1397454358000},"page":"816-821","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat"],"prefix":"10.1016","volume":"38","author":[{"given":"Christen Lykkegaard","family":"Andersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads Emil","family":"Bj\u00f8rn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Samuelsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Ejerblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savio","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bareford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Knapper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"L\u00f6fvenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olle","family":"Linder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn","family":"Andreasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Ahlstrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten Krogh","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole Weis","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herdis","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias Wirenfeldt","family":"Klausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Mourits-Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibe","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.04.002_bib0005","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.04.002_bib0010","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.leu.2404209","article-title":"A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis","volume":"20","author":"Vannucchi","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.04.002_bib0015","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis \u2013 impact on disease phenotype","volume":"79","author":"Larsen","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2014.04.002_bib0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","article-title":"Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis","volume":"40","author":"Skov","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2014.04.002_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","article-title":"Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis","volume":"87","author":"Skov","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2014.04.002_bib0030","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.04.002_bib0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000076524","article-title":"Prefibrotic chronic idiopathic myelofibrosis \u2013 a diagnostic enigma","volume":"111","author":"Thiele","year":"2004","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2014.04.002_bib0040","first-page":"1126","article-title":"Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis","volume":"85","author":"Thiele","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.04.002_bib0045","first-page":"351","article-title":"YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils","volume":"110","author":"Volck","year":"1998","journal-title":"Proc Assoc Am Phys"},{"key":"10.1016\/j.leukres.2014.04.002_bib0050","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1158\/1078-0432.CCR-08-1026","article-title":"Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma","volume":"14","author":"Biggar","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.04.002_bib0055","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/ijc.24110","article-title":"Serum YKL-40 and bone marrow angiogenesis in multiple myeloma","volume":"124","author":"Mylin","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2014.04.002_bib0060","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00384-002-0446-z","article-title":"Increased serum levels of YKL-40 in patients with inflammatory bowel disease","volume":"18","author":"Koutroubakis","year":"2003","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.leukres.2014.04.002_bib0065","first-page":"655","article-title":"Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters","volume":"19","author":"Matsumoto","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.leukres.2014.04.002_bib0070","first-page":"4364","article-title":"Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma","volume":"62","author":"Tanwar","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.04.002_bib0075","doi-asserted-by":"crossref","first-page":"15044","DOI":"10.1073\/pnas.251547398","article-title":"Gene expression in papillary thyroid carcinoma reveals highly consistent profiles","volume":"98","author":"Huang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.leukres.2014.04.002_bib0080","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0002-9440(10)63875-8","article-title":"Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses","volume":"162","author":"Sjogren","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2014.04.002_bib0085","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1158\/1078-0432.CCR-05-1317","article-title":"High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia","volume":"11","author":"Bergmann","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.04.002_bib0090","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbmt.2011.01.008","article-title":"The prognostic value of YKL-40 concentrations in nonmyeloablative conditioning allogeneic hematopoietic cell transplantation","volume":"17","author":"Morup","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.leukres.2014.04.002_bib0095","doi-asserted-by":"crossref","first-page":"15332","DOI":"10.1074\/jbc.M110.212514","article-title":"Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma","volume":"286","author":"Francescone","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2014.04.002_bib0100","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-10-0868","article-title":"YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers","volume":"10","author":"Faibish","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2014.04.002_bib0105","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1038\/onc.2009.292","article-title":"YKL-40, a secreted glycoprotein, promotes tumor angiogenesis","volume":"28","author":"Shao","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2014.04.002_bib0110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-03-2043","article-title":"Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824","volume":"64","author":"Atadja","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.04.002_bib0115","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors","volume":"19","author":"Bradbury","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.04.002_bib0120","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1073\/pnas.182372299","article-title":"The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin","volume":"99","author":"Butler","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.leukres.2014.04.002_bib0125","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2003-01-0233","article-title":"NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma","volume":"102","author":"Catley","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.002_bib0130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.leukres.2014.04.002_bib0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2014.04.002_bib0140","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1158\/0008-5472.CAN-04-0540","article-title":"The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787\/ZK222584","volume":"64","author":"Qian","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.04.002_bib0145","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.RES.0000037983.07158.B1","article-title":"Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis","volume":"91","author":"Rossig","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.leukres.2014.04.002_bib0150","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia","volume":"162","author":"Andersen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2014.04.002_bib0155","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.002_bib0160","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cca.2011.01.022","article-title":"Plasma YKL-40 levels in healthy subjects from the general population","volume":"412","author":"Bojesen","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.leukres.2014.04.002_bib0165","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/1055-9965.EPI-05-0011","article-title":"a new prognostic biomarker in cancer patients","volume":"15","author":"Johansen","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.leukres.2014.04.002_bib0170","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/fon.09.66","article-title":"YKL-40: a potential new cancer biomarker?","volume":"5","author":"Johansen","year":"2009","journal-title":"Future Oncol"},{"key":"10.1016\/j.leukres.2014.04.002_bib0175","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.002_bib0180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3324\/haematol.2010.038299","article-title":"Pathophysiology of thrombosis in myeloproliferative neoplasms","volume":"96","author":"Landolfi","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.04.002_bib0185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.04.002_bib0190","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/leu.2013.207","article-title":"Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.04.002_bib0195","first-page":"172","article-title":"Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer","volume":"53","author":"Johansen","year":"2006","journal-title":"Dan Med Bull"},{"key":"10.1016\/j.leukres.2014.04.002_bib0200","first-page":"4653","article-title":"Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence","volume":"9","author":"Trikha","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.04.002_bib0205","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.04.002_bib0210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.002_bib0215","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T19:18:59Z","timestamp":1597691939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0145212614001003"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.04.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}